Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SY-007 in Acute Ischemic Stroke
NCT04891913Phase 1Suspended
- Sponsor
- Yabao Pharmaceutical Group Co., Ltd.
- Start
- Jul 2023
- Primary completion
- Dec 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SY-007 in acute ischemic stroke (AIS) (3 cohorts), sponsored by Yabao Pharmaceutical Group Co., Ltd. Primary endpoint: Safety and tolerance of SY-007. Started Jul 2023; status: suspended.
02
Drugs
SY-007
03
Conditions
acute ischemic stroke (AIS)
Beyond the preview
Go deeper on NCT04891913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04891913.